Efficacy and side effects of mianserin, a tetracyclic antidepressant

A. WAKELING
Ph.D., B.Sc., F.R.C.Psych., D.P.M.

Academic Department of Psychiatry, Royal Free Hospital School of Medicine, London NW3 2PF

Introduction

Antidepressant drugs have been in extensive use for over 20 years. Initially 2 groups of compounds, the monoamine oxidase inhibitors (MAOI) and tricyclic compounds based on the imipramine configuration were widely used. In the early 1960's after a few years of wide use, interest in the MAOI group fell following the recognition of a serious adverse effect. Blackwell (1963) described the occurrence of hypertensive crisis with occasional fatalities when these compounds were taken with certain foodstuffs. It is of interest, however, that in recent years there has been some resurgence of interest in these compounds and the suggestion that their dangers may have been exaggerated (Tyrer, 1979) or might be ameliorated by combination with tricyclics (Pare et al., 1982). Interest in the tricyclic group however has continued unabated and over the years at least 20 antidepressants based on the original imipramine configuration have been produced. There is now a widespread and extensive accumulated experience of these compounds and although they remain the most widely prescribed antidepressant, it is now clear that they have a number of serious disadvantages. The most important of these are cardiotoxicity, potential fatality in overdose, marked peripheral anticholinergic activity and reduction in seizure threshold (Blackwell, 1981a). As these disadvantages exist to some extent with all the tricyclics produced so far, there have, not surprisingly, been active attempts to produce different and safer antidepressant compounds.

Over the last few years a number of different compounds have come into use as antidepressants and these constitute the 'second generation' antidepressant drugs. Included among these are; viloxyazine and zimelidine, both bicyclic compounds; nomifensine, a tetrahydro-isoquinoine derivative; maprotiline, a bridged tricyclic compound and the tetracyclic compound mianserin. All differ somewhat in their actions on central neurotransmitter systems and differing claims are made that their antidepressant actions are relatively free from the adverse or unwanted effects of the tricyclics. These claims should be received with caution as there has been an insufficient experience in the use of many of them. Mianserin, however, is probably the most widely used of these compounds and considerable clinical experience of its use has been accumulated over the last few years.

Mianserin

Mianserin is a tetracyclic compound structurally distinct from both the classical tricyclic antidepressants and from bridged tricyclics of the maprotiline type. It was originally designed as an anti-allergic drug, but early trials suggested mood elevating qualities and in 1972 antidepressant-like central nervous system activity was detected by computerized electroencephalographic studies in volunteers (Itil, Polvan and Hsu, 1972). Subsequently, a variety of clinical trials have indicated that mianserin possesses antidepressant activity equal to that of the widely-used tricyclic antidepressants.

Efficacy

There are particular difficulties in assessing the efficacy of new putative antidepressant compounds. The most rigorous tests of efficacy involve the use of randomized placebo-controlled double-blind clinical trials utilizing large numbers of patients, with standardized and validated procedures used for clinical diagnosis and assessment. However the use of placebo in patients with severe depressive illness when there are well-tried effective treatments raises serious ethical issues. Due to this, new antidepressant compounds are usually compared in trials with standard tricyclic antidepressants. Such trials not surprisingly can give rise to complex problems of interpretation.
Placebo controlled trials. Smith, Naylor and Moody (1978) demonstrated the superiority of mianserin over placebo in an important trial including 41 severely depressed women. However, this trial lasted only 2 weeks because of the ethical considerations involved. Two further placebo controlled trials utilizing mildly depressed patients suggested active antidepressant effect for mianserin (Murphy, Donald and Molla, 1976; Brancennonier, Cole and Ghazvinian, 1981).

Comparison with tricyclic antidepressants. A large number of double-blind trials of varying methodological sophistication comparing mianserin with standard tricyclic antidepressants have been reported (Pinder and Fink, 1982). These include comparison with amitriptyline (Wheatley, 1975; Coppen et al., 1976; Montgomery et al., 1978; Murphy and Bridge- man, 1978; Daly, Brown and Morgan, 1979; Kretschmar, 1980) with imipramine (Murphy, 1975; Pichot, Dreyfus and Pull, 1978) and with clomipramine (Blaha, Pinder and Stulemeijer, 1980; De Buck, 1980). The detection of differences in efficacy between 2 compounds both having active properties, in small groups of patients is difficult. It is therefore perhaps not surprising that almost all of these comparisons between mianserin and tricyclics have concluded that they are indistinguishable in efficacy and onset of action. An important factor however emanating from these trials is the apparent paucity of side effects emerging on treatment with mianserin. Daily dosage in these studies ranged from 20–30 mg for mianserin and 75–300 mg for the tricyclics.

Side effects

Mianserin has sedative properties and drowsiness is the most frequently reported side effect. However, this often diminishes within the first week. The clinical trials suggest that peripheral anticholinergic effects are rare and occur to a less extent than with tricyclics. These observations from therapeutic trials are supported by experimental double-blind studies in depressed patients (Ghose, Coppen and Turner, 1976; Wilson, Petrie and Ban, 1980) and in normal volunteers (Kopera, 1980).

A further important feature emerging from clinical trials with mianserin is an apparent lack of cardiovascular problems such as increased heart rate and hypotension. Burgess et al. (1979), in an analysis of the cardiovascular effects of mianserin and other antidepressants, reported that mianserin lacked the cardiotoxic and negative inotropic effects of the tricyclic antidepressants. Experimental studies in intact animal hearts, whole animals and in healthy subjects further demonstrate a lack of cardiotoxicity for mianserin (Harper and Hughes, 1977; Kopera et al., 1980).

The lack of cardiotoxicity with mianserin is probably associated with its apparent safety in overdose. Overdose with mianserin commonly causes drowsiness, but there is an absence of the more serious complications found in tricyclic or maprotiline overdose. Shaw (1980) in a survey of 84 cases of mianserin overdose from the London Poisons Unit reported no deaths and an absence of cardiac arrhythmias and convulsions. Management of mianserin overdose is limited to gastric lavage within the first 2 hr after ingestion, with monitoring of vital functions. In contrast to Shaw’s findings however, Edwards (1979) reporting data from the Committee on Safety of Medicines indicates that mianserin accounts for about 11% of reported antidepressant related convulsions. This clearly requires continuing observation and draws attention to the need for full reporting to the relevant safety bodies of all adverse drug effects. The other serious side effect of mianserin is the occasional occurrence of blood dyscrasias.

Blood dyscrasias. Between January 1974 and October 1981, the Committee on Safety of Medicines received 17 reports of blood dyscrasias associated with mianserin. These included 7 cases of agranulocytosis, 8 cases of granulocytopenia, one case of generalized leucopenia and one case of pancytopenia. Curson and Hale (1979) and McHarg and McHarg (1979) published some details on 2 of these cases. Four of them were reported to the Australian Drug Evaluation Committee (1980) following the introduction of mianserin in Australia in April 1978. Adams et al. (1983), in this journal, provide clinical details on a further 4 of these cases, one of whom died. In the last few months, 2 additional cases of mianserin-induced agranulocytosis have been reported (Page, 1982; Achar, 1982).

White cell depression usually occurs early, typically at between 4 and 6 weeks after the start of treatment. It typically presents with oral ulceration and a sore throat. The neutrophil count in most of these cases was severely reduced to 0·2 × 10⁹/litre or less, but, typically, complete recovery occurred once the drug was withdrawn.

This association of mianserin with a small number of cases of blood dyscrasias should be viewed against the background that all psychotropic drugs are reported as being associated with some form of blood dyscrasia. Nevertheless, it dictates that all patients receiving mianserin should be carefully observed particularly during the first few weeks of treatment. In the event of the patient developing symptoms of infection such as fever, stomatitis or sore throat the drug should be stopped immediately and full haematological investigation started. It might be prudent, where possible, for patients to have regular blood counts with a particular focus at between 4 and 6 weeks. It should be emphasized however that the key...
Mianserin—efficacy and side effects

Conclusions

There is evidence to indicate that mianserin has antidepressant activity. It is generally well tolerated and appears to have a low propensity for interaction with many of the commonly used drugs. Due to its apparent lack of serious side effects, particularly the absence of cardiotoxicity and anticholinergic effects and its safety in overdosage, it is now in widespread use. It is widely used in general practice and primary care settings particularly among the elderly and those with medical and cardiovascular problems. The recent reports of severe blood dyscrasias in a few patients receiving mianserin should, however, induce caution. Blackwell (1981b) has cogently pointed out 'that a consistent feature of the literature on all psychotropic drugs is the extended time periods that occur between the introduction of a new compound and the discovery of its full range of adverse effects'. He calls attention to the fact that new side effects such as speech blockage are being recognized after 20 years of extensive use of the tricyclic antidepressants. It is important, therefore, to maintain a high level of vigilance in the use of all psychotropic drugs and to be alert to the possibility of new adverse effects arising in apparently safe compounds.

Antidepressants are powerful drugs and as yet their mode of action is incompletely understood. There is a consensus of opinion that these compounds are overprescribed particularly in the primary care setting. Yet it is precisely here that high standards of clinical monitoring are often lacking.

References


(Received 26 October 1982)